Table 1. . Patient characteristics (n = 128).
| Characteristic | Number (%) |
|---|---|
| Age (years) | |
| – 65–70 | 57 (44.5) |
| – 70–75 | 45 (35.2) |
| – >75 | 26 (20.3) |
| Co-morbidities, n | |
| – 0 | 32 (25.0) |
| – 1 | 45 (35.2) |
| – 2 | 33 (25.8) |
| – >2 | 18 (14.1) |
| Metabolic disorders at baseline | |
| – None | 107 (83.6) |
| – Impaired glucose tolerance | 6 (4.7) |
| – Diabetes | 15 (11.7) |
| Histology | |
| – Ductal | 116 (90.6) |
| – Lobular | 10 (7.8) |
| – Other | 2 (1.6) |
| Immunohistochemical features | |
| – Luminal A | 23 (18.0) |
| – Luminal B | 26 (20.3) |
| – HER2 positive | 42 (32.8) |
| – Triple negative | 37 (28.9) |
| Chemotherapy regimens | |
| – Antracyclines and taxanes (sequential) | 61 (47.7) |
| – Antracyclines only | 33 (25.8) |
| – Taxanes only | 23 (18.0) |
| – No antracyclines or taxanes | 11 (8.6) |
| – Anti-HER2 agents | 42 (32.8) |
| Dose reduction of chemotherapy | |
| – No | 105 (82.0) |
| – Yes | 23 (18.0) |
| Early discontinuation of chemotherapy | |
| – No | 114 (90.1) |
| – Yes | 14 (10.9) |
| Toxicities during chemotherapy (≥G2) | |
| – Leukopenia/neutropenia | 27 (21.1) |
| – Febrile neutropenia | 5 (3.9) |
| – Nausea/vomiting | 32 (25.0) |
| – Diarrhea | 9 (7.1) |
| – Mucositis | 11 (8.6) |
| – VTE | 9 (7.1) |
| Recurrence | |
| – No | 110 (85.9) |
| – Yes | 18 (14.1) |
VTE: Venous thromboembolism.